Urology Practice Management Considerations & Treatment Selection for Special Populations with Metastatic CRPC

home / peers-and-perspectives / urology-practice-management-considerations-and-treatment-selection-for-special-populations

Christopher M. Pieczonka, MD and Jose De La Cerda, MD, MPH engage in a comprehensive discussion on the nuances of abiraterone formulations for treating metastatic castration-resistant prostate cancer (mCRPC). They explore patient assessment, treatment considerations for special populations, and clinical practice management tailored to the diverse needs of patients with mCRPC.

© 2024 MJH Life Sciences

All rights reserved.